Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

In this article, I noted the prospects that this company is achieving regarding the development of its pipeline drug known as pegozafermin for the treatment of patients with metabolic-associated ...

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

H.C. Wainwright reiterated its Buy rating and $29.00 price target for 89bio Inc . (NASDAQ:ETNB) shares. According to InvestingPro data, the stock currently trades at $6.31, near its 52-week low of $5.

Additionally, the ongoing Phase 3 ENLIGHTEN program in NASH, which investigates pegozafermin in both non-cirrhotic and cirrhotic conditions, has garnered significant interest from key opinion ...

周一，Leerink Partners分析师Thomas Smith将89bio Inc. (NASDAQ: ETNB )的目标价从34美元上调至37美元，同时重申对该股的"优于大市"评级。目前，该股交易价格为9.60美元，远低于分析师12美元至49美元的更广泛目标区间。根据 InvestingPro ...

“We remain confident in pegozafermin’s potential as a potent anti-fibrotic agent with broad cardio-metabolic benefits. With a strengthened leadership team, commercial-scale manufacturing ...

该公司对这家生物制药公司前景的信心与其pegozafermin治疗严重高甘油三酯血症(SHTG)的III期ENTRUST研究进展密切相关。该研究已成功完成患者招募，预计将在2025年下半年公布顶线数据。 ENTRUST试验是 ...

The company's lead candidate, pegozafermin, is currently in Phase III clinical trials for the treatment of Metabolic Associated Steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).